Prevention of hyperacute xenograft rejection by polyclonal antibodies

通过抗供体淋巴细胞和红细胞的多克隆抗体预防超急性异种移植排斥反应。T.Murakami，S.Hujita，Y.Hayasaka，M.Shinkai，Y.Funakoshi，T.Kawai，S.Fuchinoue，S.Teraoka，T.Agishi和K.Ota。东京女子医学院肾脏中心外科，东京，据报道，静脉注射高剂量的免疫球蛋白（IVIG）可延迟超急性排斥反应（HAR）的发生。异种移植物的不协调性为探讨静脉注射丙种球蛋白（IVIG）预防刘易斯大鼠心脏移植后HAR的可能性，在移植前即刻用豚鼠淋巴细胞和红细胞免疫家兔，制备特异性多克隆抗体（抗GP-pAb）。刘易斯大鼠静脉注射20%人血白蛋白1 ml或1.5 ~ 30 mg/kg。血管化的心脏异种移植物的收缩时间从平均12.2分钟延长至超过7小时，这与所施用的抗体的剂量密切相关（r=0.958）。免疫病理学研究显示排斥移植物中弥漫性C3和纤维蛋白原沉积，以及少量大鼠IgM血管沉积。在用抗体处理的功能性移植物中，在移植后早期观察到兔IgG沿着内皮沉积沿着，并且用托伊梅变得更广泛，而C3、纤维蛋白原和大鼠IgM的沉积最小。结论：兔抗GP-pAb.在高剂量下防止天然抗体与移植物内皮的结合并调节补体激活。

Prevention of hyperacute xenograft rejection by polyclonal antibodies against donor luymphocytes and red cells.T.Murakami, S.Hujita, Y.Hayasaka, M.Shinkai, Y.Funakoshi, T.Kawai, S.Fuchinoue, S.Teraoka, T.Agishi, and K.Ota.Dept.of Surgery, Kidney Center, Tokyo Womens Medical College, Tokyo, Japan.Intravenous administration of immunoglobulin (IVIG) at a high dosage has been reported to delay an initiation of hyperacute rejection (HAR) of the discordant xeno-grafts. In order to investigate possibility of preventing HAR of guinea pig hearts grafted to Lewis rats by IVIG,specific polyclonal antibodies were produced by immunizing rabbits against guinea pig lymphocytes and red cells (anti-GP-pAb)Immediately before transplantation, the Lewis rats intravenously received either 1 ml of 20% human albumin as a control or 1.5-30mg/kg of the antibodies. Contraction time of the vascualized cardiac xenografts was extended from a mean of 12.2 minutes to longer than 7 hours intimately depending upon the doses of the antibodies administered (r=0.958). Immunopathological studing showed diffuse deposition of C3 and fibrinogen with a small amount of vascular deposits of rat IgM in the rejected grafts. In the functioning grafts treated with the antibodies, rabbit IgG deposition along endothelium was observed early after transplantation and becam more extensive with toime, while deposits of C3, fibrinogen and rat IgM were minimal. In conclusion, our data suggest that the rabbit antiGP-pAb. at a high dosage prevent the binding of the natural antibodies to the graft endothelium and modulate the complement activation.